Skip to main content
Clinical Trials/NCT04457063
NCT04457063CompletedPhase 2

Endothelial Cell Loss Following Toric ICL Implantation for Correction of Myopia and Astigmatism After Penetrating Keratoplasty

Alexandria University1 site in 1 country8 target enrollmentStarted: July 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
8
Locations
1
Primary Endpoint
Refraction

Study Overview

Brief Summary

This work aimed at the assessment of corneal endothelial cell loss after toric ICL implantation for correction of myopia and astigmatism after penetrating keratoplasty.

Detailed Description

Penetrating keratoplasty (PKP) is considered a safe and effective procedure.This work aimed at the assessment of corneal endothelial cell loss after toric ICL implantation for correction of myopia and astigmatism after penetrating keratoplasty.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction

Exclusion Criteria

  • Less than 18 and unable to give informed consent

Outcomes

Primary Outcomes

Refraction

Time Frame: 1 year

Refractive measured by Diopter

Visual acuity

Time Frame: 1 year

The decimal snellens

Intra-ocular pressure

Time Frame: 1 year

mg

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials